GOA Therapeutics Unveils New Data for GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and PoisoningIn a porcine model of severe acute alcohol intoxication, GOA26 demonstrated a rapid reduction in blood alcohol concentration and multi-system biochemical recovery across metabolic, muscle, hematological and liver biomarkers.
GOA Therapeutics Files with SEC for Proposed Public Offering, Contemplates Issuing Up to $300 Million in StockFinancing strategy designed to support GOA26 through clinical development, manufacturing, regulatory activities and commercialization planning
